Compare SPWH & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPWH | NSRX |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 63.4M |
| IPO Year | 2014 | 2025 |
| Metric | SPWH | NSRX |
|---|---|---|
| Price | $1.41 | $5.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $2.95 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 354.1K | 5.8K |
| Earning Date | 12-04-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,214,723,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $0.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $5.50 |
| 52 Week High | $4.33 | $9.99 |
| Indicator | SPWH | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 36.45 |
| Support Level | $1.36 | $5.50 |
| Resistance Level | $1.55 | $7.70 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 27.50 | 4.09 |
Sportsman's Warehouse Holdings Inc together with its subsidiaries operates as an outdoor sporting goods retailer. It provides a one-stop shopping experience that equips customers with the right quality, brand name hunting, shooting, fishing, and camping gear to maximize enjoyment of the outdoors. The company offers products in the categories of Camping, Apparel, Fishing, Footwear, Hunting and shooting, and Optics, Electronics, Accessories, and Other products. It provides products such as Backpacks, Jackets, Camp essentials, Hiking boots, GPS devices, ATV accessories and Fishing rods, among others.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.